Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Firmonertinib + Bevacizumab Neoadjuvant Therapy in EGFR-mutated NSCLC
NCT07182708Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07182708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182708.